Cargando…
Homogeneous antibody–angiopep 2 conjugates for effective brain targeting
Antibody-based therapy has shown great success in the treatment of many diseases, including cancers. While antibodies and antibody–drug conjugates (ADCs) have also been evaluated for central nervous system (CNS) disorders as well as brain tumors, their therapeutic efficacy can be substantially limit...
Autores principales: | Anami, Yasuaki, Xiong, Wei, Yamaguchi, Aiko, Yamazaki, Chisato M., Zhang, Ningyan, An, Zhiqiang, Tsuchikama, Kyoji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8979263/ https://www.ncbi.nlm.nih.gov/pubmed/35425350 http://dx.doi.org/10.1039/d1ra08131d |
Ejemplares similares
-
Homogeneity of antibody-drug conjugates critically impacts the therapeutic efficacy in brain tumors
por: Anami, Yasuaki, et al.
Publicado: (2022) -
Glutamic acid–valine–citrulline linkers ensure stability and efficacy of antibody–drug conjugates in mice
por: Anami, Yasuaki, et al.
Publicado: (2018) -
Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
por: Yamazaki, Chisato M., et al.
Publicado: (2021) -
Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016) -
Enhanced anti-angiogenetic effect of transferrin receptor-mediated delivery of VEGF-trap in a glioblastoma mouse model
por: Zhao, Peng, et al.
Publicado: (2022)